Elizabeth R. Plimack, MD, MS, chief of the Division of Genitourinary Medical Oncology, director of Genitourinary Clinical Research, and professor in the Department of Hematology/Oncology at Fox Chase…
Bradley McGregor, MD, clinical director at Lank Center for Genitourinary Oncology, senior physician at Dana-Farber Cancer Institute, and instructor of medicine at Harvard Medical School, discusses a new…
Daniel George, MD, questions whether debulking nephrectomy is still necessary in the age of targeted therapies. In a one-sided non-inferiority study, sunitinib alone was compared to nephrectomy. The…
In an interview during the 2020 OncLive® State of the Science Summit™ on Advanced Melanoma, Tracey Liebman, MD, assistant professor in the Ronald O. Perelman Department of Dermatology at the NYU…
Mikkael Sekeres, MD, director of the Leukemia Program and vice-chair for Clinical Research at the Cleveland Clinic Taussig Cancer Institute, discusses a phase 2 study of pevonedistat plus azacitidine…
Studies of pembrolizumab have shown promising antitumor activity across a wide cohort of patients with clear cell renal cell carcinoma (ccRCC). The results of a recent study, named…
According to findings in an extended follow-up of the ongoing CheckMate 214 trial, nivolumab plus ipilimumab is more effective than sunitinib as first-line treatment for patients with advanced…
In this webinar hosted by the Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology, Pasi Jänne, MD, PhD, Julia Rotow, MD, and Mark Awad, MD, PhD, discuss how…
In a study of patients with advanced melanoma treated with single-agent nivolumab or pembrolizumab, 25.8% achieved a complete response (CR). Approximately four out of five patients with advanced…